Presentation is loading. Please wait.

Presentation is loading. Please wait.

Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy  Eva Wollmann,

Published byΙσίδωρα Ελευθερόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy  Eva Wollmann,"— Presentation transcript:

1 Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy  Eva Wollmann, MD, Christian Lupinek, MD, Michael Kundi, PhD, Regina Selb, MSc, Verena Niederberger, MD, Rudolf Valenta, MD  Journal of Allergy and Clinical Immunology  Volume 136, Issue 3, Pages e7 (September 2015) DOI: /j.jaci Copyright © 2015 The Authors Terms and Conditions

2 Fig 1 Courses of geometric means and 95% CIs of Bet v 1–specific IgE (A: ImmunoCAP; B: ISAC) and IgG (C: ImmunoCAP; D: ISAC) levels (y-axes) over the study period (x-axes) for placebo- (blue), fragment- (green), and trimer-treated patients (orange). *P < .05 and **P < .01. Asterisks show the significance of changes within particular groups from the time point before treatment to after treatment, from after treatment to after season, and from after season to after 1 year. ISU, ISAC Standardized Unit. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

3 Fig 2 Association of alterations in Bet v 1–specific IgE levels determined by ISAC and nasal allergen tolerance. Y-axes (positive range) indicate increased allergen-specific tolerance, wherein 1-point increase indicates tolerance of a 10-fold higher allergen concentration and 1-point decrease indicates a 10-fold higher sensitivity. X-axes indicate the log fold changes of Bet v 1–specific IgE when comparing prestudy levels (ie, before treatment; see Fig 1 and Fig E1) to levels after the pollen season (ie, after season; see Fig 1 and Fig E1). ISU, ISAC Standardized Unit. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

4 Fig E1 Timeline of the SIT study. Blue arrows indicate the time points when blood samples were taken (before treatment, after treatment, after season, after 1 year). Nasal provocation tests analyzed in this study were performed before treatment (November/December 2000) and after season (May 2001). Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

5 Fig E2 Courses of geometric means and 95% CIs of Aln g 1 (A and B) and Cor a 1 (C and D)-specific IgE and IgG levels. *P < .05 and **P < .01. Asterisks show the significance of changes within particular groups from the time point before treatment to after treatment, from after treatment to after season, and from after season to after 1 year. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

6 Fig E3 Course of geometric means and 95% CIs of Mal d 1 (A and B) or Pru p 1 (C and D)-specific IgE and IgG levels. *P < .05 and **P < .01. Asterisks show the significance of changes within particular groups from the time point before treatment to after treatment, from after treatment to after season, and from after season to after 1 year. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

7 Fig E4 Association of alterations in Bet v 1–specific IgE levels determined by ImmunoCAP and nasal allergen tolerance. Y-axes (positive range) indicate increased allergen-specific tolerance, wherein 1-point increase indicates tolerance of a 10-fold higher allergen concentration and 1-point decrease indicates a 10-fold higher sensitivity. X-axes indicate the log fold changes of Bet v 1–specific IgE when comparing prestudy levels (ie, before treatment; see Fig 1 and Fig E1) to levels measured after the pollen season (ie, after season; see Fig 1 and Fig E1). Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

Download ppt "Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy  Eva Wollmann,"

Similar presentations

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study  Anna.

Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study  Anna.
Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy  Christian Lupinek, Kurt Derfler, Silvia Lee, Thomas Prikoszovich, Oliver Movadat,

Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy  Christian Lupinek, Kurt Derfler, Silvia Lee, Thomas Prikoszovich, Oliver Movadat,
Volume 11, Pages (September 2016)

Volume 11, Pages (September 2016)
Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines 

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines 
Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies  Marija Geroldinger-Simic, MD, Thomas Zelniker,

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies  Marija Geroldinger-Simic, MD, Thomas Zelniker,
Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Anthroposophic lifestyle is associated with a lower incidence of food allergen sensitization in early childhood  Sara Fagerstedt, MSc, Helena Marell Hesla,

Anthroposophic lifestyle is associated with a lower incidence of food allergen sensitization in early childhood  Sara Fagerstedt, MSc, Helena Marell Hesla,
High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE  Elizabeth A. Erwin,

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE  Elizabeth A. Erwin,
Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 
Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE  Eva-Maria Varga, MD, Fahima Kausar, MSc, Werner.

Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE  Eva-Maria Varga, MD, Fahima Kausar, MSc, Werner.
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Erika Lerch, MD, Ulrich R. Müller, MD 

Erika Lerch, MD, Ulrich R. Müller, MD 
Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule  Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,

Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule  Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,
Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,
Julie Wang, MD, James H. Godbold, PhD, Hugh A. Sampson, MD 

Julie Wang, MD, James H. Godbold, PhD, Hugh A. Sampson, MD 
Persistence of the IgE repertoire in birch pollen allergy

Persistence of the IgE repertoire in birch pollen allergy
Specific IgE and IgG measured by the MeDALL allergen-chip depend on allergen and route of exposure: The EGEA study  Valérie Siroux, PhD, Christian Lupinek,

Specific IgE and IgG measured by the MeDALL allergen-chip depend on allergen and route of exposure: The EGEA study  Valérie Siroux, PhD, Christian Lupinek,
Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies 

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies 

Similar presentations

Ads by Google